

## Maintaining Physical Activity during (Head and Neck) Cancer Treatment (MPACT): Results of a Pilot Controlled Trial

Shuang G. Zhao MSE<sup>1</sup>, Neil B. Alexander MD<sup>2,3</sup>, Zora Djuric PhD<sup>4</sup>, Jessica Zhou MD<sup>1</sup>, Yebin Tao MS<sup>5</sup>, Matthew Schipper PhD<sup>1,5</sup>, Felix Y. Feng MD<sup>1</sup>, Avraham Eisbruch MD<sup>1</sup>, Francis P. Worden MD<sup>6</sup>, Scott J. Strath PhD<sup>7</sup>, Shruti Jolly MD<sup>1,8</sup>

<sup>1</sup>Department of Radiation Oncology, <sup>2</sup>Division of Geriatric and Palliative Medicine, Department of Internal Medicine, <sup>4</sup>Department of Family Medicine, <sup>5</sup>Department of Biostatistics, <sup>6</sup>Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor MI

<sup>3</sup>Geriatrics Research, Education and Clinical Center, <sup>8</sup>Department of Radiation Oncology, Veterans Affairs Ann Arbor Health Care System, Ann Arbor MI

<sup>7</sup>Department of Kinesiology, Center for Aging and Translational Research, University of Wisconsin-Milwaukee, Milwaukee WI

**Running title:** MPACT intervention in Head and Neck Cancer patients

Correspondence should be addressed to Shruti Jolly M.D., Department of Radiation Oncology, University of Michigan; UHB2C447, SPC 5010; 1500 East Medical Center Drive; Ann Arbor, MI 48109-5010; telephone (734) 936-7810; fax (734) 763-7370; e-mail: [shrutij@med.umich.edu](mailto:shrutij@med.umich.edu)

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version record](#). Please cite this article as [doi:10.1002/hed.24162](https://doi.org/10.1002/hed.24162).

## Abstract

### *Background*

Concurrent chemotherapy and radiation (CCRT) to treat head and neck cancer is associated with significant reductions of weight, mobility and quality of life (QoL). An intervention focusing on functional exercise may attenuate these losses.

### *Methods*

We allocated patients to a 14-week functional resistance and walking program designed to *maintain physical activity* during *cancer treatment* (MPACT, n=11), or to usual care (Control, n=9). Outcomes were assessed at baseline, 7 and 14 weeks.

### *Results*

Compared to controls, the MPACT participants had attenuated decline or improvement in several strength, mobility, physical activity, diet, and quality of life endpoints. These trends were statistically significant ( $p < 0.05$ ) in knee strength, mental health, head and neck QoL, and barriers to exercise.

### *Conclusion*

In this pilot study of head and neck cancer patients undergoing CCRT, MPACT training was feasible and maintained or improved function and QoL, thereby providing the basis for larger future interventions with longer follow-up.

## Introduction

Head and neck cancer affects more than 52,000 Americans yearly, accounting for 5% of cancers worldwide, and with a 5-year overall survival of 57%.<sup>(1)</sup> Historically, most head and neck cancer occurs in older men with a history of significant tobacco and alcohol exposure. However, recent evidence suggests a shift in the epidemiology of head and neck cancer with a rise in the incidence of Human Papillomavirus (HPV)-positive disease among nonsmokers who present at an earlier age. Although HPV-positive cancers are associated with more extensive nodal disease, they generally respond better to treatment and are associated with improved overall survival resulting in an ever-growing number of cancer survivors.<sup>(2, 3)</sup> Given the higher rates of tumor response and better prognosis in HPV positive cancers, the focus in head and neck cancer research has changed from attempting to increase tumor response rates to identifying strategies that can decrease long-term treatment-related effects.

Treatment of head and neck cancer with concurrent chemotherapy and radiation (CCRT) with curative intent may cause side effects leading to deterioration of long-term quality of life (QoL) and disability that persists years after treatment. head and neck cancer and its treatment can severely impact the ability to eat, speech, physical appearance, and emotional well-being.<sup>(4, 5)</sup> These side effects may worsen body image, self-esteem, and social interactions in patients with head and neck cancer.<sup>(6, 7)</sup> To improve the QoL of cancer patients, cost-effective clinical paradigms that promote overall well-being, including lifestyle changes, are essential.<sup>(8)</sup>

Head and neck cancer patients often experience significant unintentional weight loss despite adequate nutritional support.<sup>(9, 10)</sup> A large percentage of this weight loss is in lean body (muscle) mass.<sup>(8, 11)</sup> Muscle mass loss is associated with disability, deficits in functional mobility and a decrease in physical activity level, as well as reduced quality of life and worse overall patient prognosis.<sup>(12-18)</sup> Moreover, muscle mass

loss occurs despite aggressive nutritional interventions to maintain body weight<sup>(10)</sup>, and dietary interventions alone increase fat mass with no effect on lean body mass<sup>(17)</sup>. Patients with head and neck cancer are generally less active than other patients with cancer, suggesting that sedentary behavior may worsen muscle mass loss through muscle disuse and deconditioning.<sup>(12)</sup> Exercise and a focus on physical activity may counteract this unintentional weight loss, muscle mass loss and attenuate the decline in QoL.

Exercise training has been demonstrated to improve strength, function, and quality of life in patients undergoing treatment for cancers other than head and neck cancer, including breast, prostate, lung, and hematologic malignancies.<sup>(19-28)</sup> However, many of those studies have focused on breast and prostate cancer patients, who often are in better health at baseline, whose definitive treatment may not be as debilitating, and who do not suffer as much muscle mass loss compared with head and neck cancer patients. At diagnosis, head and neck cancer patients present with low baseline physical activity levels that remain low following treatment, with more than half of patients unable to return to work after treatment.<sup>(18, 29)</sup> Finally, while most studies have focused on exercise in cancer treatment survivors, initiating exercise interventions during definitive treatment may be more optimal<sup>(21-23, 25, 28)</sup>, thereby providing the potential to limit treatment side-effects and provide techniques that can accelerate recovery.

We conducted a pilot controlled trial to assess the feasibility and efficacy of a functional resistance and walking exercise intervention (MPACT, Maintaining Physical Activity during Cancer Treatment) both during CCRT and in short term follow-up after treatment. Our primary aims were to assess the benefits of MPACT on muscle strength, functional mobility, and self-reported QoL in head and neck cancer patients. Our hypothesis was that, compared to usual care controls, participants allocated to the MPACT intervention would exhibit less CCRT-induced decline and accelerated post-CCRT recovery in a number of key measures, including muscle strength, functional mobility and QoL. Secondary aims were to assess the benefit of MPACT on other key endpoints including body mass index (BMI), lean body mass, diet,

activity (both self-reported and objectively measured), sleep, CCRT toxicity, and barriers to exercise. Data from this study can be used to guide a more extensive intervention with longer term follow-up to demonstrate not just attenuation of the CCRT effect, but also long term maintenance and enhancement of post-CCRT gains.

## **Methods**

### Participants

Eligibility criteria included patients 40 years or older with AJCC stage II-IV head and neck squamous cell carcinoma who were beginning first-line CCRT without surgery and who were capable of understanding and adhering to the protocol requirements. Exclusion criteria included: substantial dementia (Folstein Mini-Mental State Examination score of <24 out of 30), active cardiopulmonary disease, acute medical conditions not related to their head and neck cancer such as acute flare-up of a joint condition or infection, refusal of a percutaneous endoscopic gastrostomy (PEG) tube for supplementary nutrition if determined as necessary by the treating physician, active treatment for another cancer, exercising at a moderate intensity for more than 150 minutes per week, or receiving physical therapy at the time of enrollment. Age 40 was used as the minimum given the relatively small number of younger patients who present with head and neck cancer especially at the Veterans Affairs treating facility. .

### Design and participant allocation

Following institutional review board approved informed consent, participants completed baseline assessments (see below) and were then allocated to MPACT or Control groups following stratification by site, Veterans Affairs Ann Arbor Health Care System (VA) or University of Michigan (UM). Then, using a computerized algorithm, allocation to MPACT or Control group was based on a minimization procedure<sup>(30)</sup> which minimized the imbalance between the MPACT and control groups in key potential

confounding variables, namely age, gender, and functional mobility (represented by comfortable gait speed).

Using intensity modulated radiotherapy, patients were treated with platinum-based CCRT to a total dose of 70 Gray. CCRT was delivered over 7 weeks to the primary tumor and bilateral neck. Chemotherapy was given weekly at the VA and every three weeks at UM as tolerated by the patient. As per standard of care, all participants were seen by the attending physician and care team at least weekly. All participants met with a dietician before the initiation of CCRT, and then again at the discretion of the attending physician if the participant experienced greater than a 5-10% decrease in body mass. Only one participant (a control) utilized a PEG tube at baseline. All participants were reassessed at weeks 7 and 14 (see below), the latter coinciding with a standard follow-up visit with the attending physician and care team.

#### Assessments

Key factors thought to change with CCRT and the MPACT intervention, including muscle strength, functional mobility, self-reported quality of life (QoL) and physician reported CCRT toxicity, were assessed at baseline, 7 weeks, and 14 weeks. In order to determine feasibility for future studies and after initial accrual of participants in both groups, a subsequent participants recruited into the study wore an actigraph for 7 days (objective physical activity assessment) and completed a 7-day diet journal (nutrition assessment). Assessors were blinded to experimental group allocation.

*Muscle Strength:* Elbow flexion and knee extension strength (in Newton-meters) were assessed on the dominant side using an isokinetic dynamometer and standard positioning techniques (Biodex Medical Systems, Shirley, New York). Grip strength (in kilograms) was assessed on the right side using a hand dynamometer (Patterson Medical, Bolingbrook, Illinois). The best of 2 trials was used as the outcome unless the difference between the first and second trials was greater than 10%, in which case a third trial was done.

*Functional mobility:* These assessments followed standard literature-based protocols. In addition to comfortable gait speed (in m/sec) over a 6 meter distance, the timed up and go (in seconds) was assessed as the time to rise from a chair, walk 3 meters away, and then return to the chair and sit down<sup>(31)</sup>; the average of two trials was used for each outcome measure. For the six minute walk, participants were told to cover as much distance (in feet) as possible comfortably during a 6-minute hallway walk.

*Self-reported Quality of life:* Participants completed the Medical Outcomes Study Short Form-36 (SF-36), with analyses conducted of the summarized Physical and Mental domains as well as eight subcomponents including Physical Function, Role-Physical, Role-Mental, Role-Emotional, Vitality, Mental Health, Social Functioning, Pain, and General Health.<sup>(32)</sup> The 6-item MOS Sleep Problem Index (MOS-Sleep 6) was used to measure sleep initiation, maintenance, respiratory problems, adequacy, and somnolence, with higher scores indicating more sleep disturbance and worse sleep quality.<sup>(33)</sup>

*BMI and lean body mass:* Lean body mass (%) was calculated using Dual-energy X-ray Absorptiometry (DEXA) as described previously.<sup>(11)</sup>

*Self-reported physical activity:* The Physical Activity Scale for the Elderly (PASE) questionnaire assessed the frequency of performing a variety of daily activities including muscle strength/endurance, housework, sports, tasks involving standing or walking, and gardening. The PASE score was calculated using the Washburn approach<sup>(34)</sup>, with higher scores indicating higher activity level. Missing data was handled by proportionally reweighting the remaining questions such that the sum of the weights was conserved.

*Objectively assessed physical activity:* A subgroup of participants wore an Actigraph GT3x+ accelerometer (Actigraph, Fort Walton Beach, FL) over the right hip for seven consecutive days. Individuals were asked to remove the device during sleep, bathing, and any other aquatic related activities. Actigraph data processing followed previously published standards<sup>(35)</sup>. Non-wear time was defined as > 60 consecutive minutes of zero activity (counts/minute), allowing for a tolerance spike of two minutes with activity counts per minute between 0 and 100<sup>(35)</sup>. To determine valid days of wear (> 10 hours/day of wear time) non-wear time was subtracted from 24 hours of data collected<sup>(36)</sup>. Total activity

counts per minute during wear time were classified into activity intensity levels using previously established standards (0-99 counts = sedentary; 100-759 counts = light; 760-1951 = lifestyle;  $\geq 1952$  = moderate to vigorous activity<sup>(37, 38)</sup>. The proportion of time spent in each activity intensity level was calculated by dividing minutes of intensity specific movement by the total minutes of wear time. Further, each time a minute of activity broke the  $<100$  to the  $>100$  counts this activity was coded as a sedentary transition. For pilot purposes in the current paper we report proportions of sedentary and lifestyle time, as well as transitions in movement posture from sitting to standing.

*Head and neck specific quality of life:* The 20-question Head and Neck Quality of Life questionnaire was used to assess disease specific QoL across four domains: eating, communication, pain, emotion, as well as an additional single question assessing “waking up frequently at night” due to the patient’s head and neck condition.<sup>(39)</sup> The analysis included both the individual questions as well as the overall domain scores, which were transformed to a 0-100 scale, with higher scores indicating worse problems.

*Barriers to Exercise:* In a “Barriers to Exercise” survey described previously<sup>(40)</sup>, participants rated the frequency of 34 items that may have interfered with exercise in the past 4 weeks on a 1 to 5 Likert scale. Sample items included “lack of interest in exercise”, “lack of equipment”, “fatigue”, “family responsibilities,” as well as more treatment-specific items including “difficulty swallowing”, “decreased food intake”, “dry mouth or throat,” and “need for tube feedings”. Higher scores indicated increased frequency that the perceived barrier interfered with exercise.

*Smoking and alcohol use:* Smoking habits were assessed using the Fagerstrom Nicotine Dependence Test, with higher scores associated with greater dependency.<sup>(41)</sup> Alcohol use was assessed using the Alcohol Use Disorders Identification Test (AUDIT), with higher scores correlating with more problematic usage.<sup>(42)</sup>

*Diet:* A subgroup of participants was asked to keep 7-day diet journals through week 7. These diet journals were enumerated for servings of protein, dairy, grains, fruit and vegetables and meal



replacements. Daily totals in each category were calculated as was a “solid food” summary score that added daily servings of grains, protein, fruits and vegetables.

*CCRT toxicity:* Data on adverse events were collected prospectively by the treating physician from the time of the initial CCRT through the end of the study. Adverse events were identified based on descriptions and grading scales found in the revised National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE)<sup>(43)</sup>. The proportion of patients experiencing toxicities of interest, defined as Grade 3 or higher, blood count changes, mucositis, xerostomia, or dermatitis were assessed.

### MPACT Intervention

The MPACT intervention was delivered at a clinical research center by a trainer following CCRT initiation up to week 7 and then post-CCRT at home, with weekly trainer phone calls from weeks 8 to 14. The use of on-site plus follow-up telephonic support was consistent with the most effective mode of delivery of cancer rehabilitation programs.<sup>(44)</sup> Controls received standard treatment including active nutritional surveillance but were neither encouraged nor discouraged to exercise. The initial seven week MPACT program included initiation of a functional resistance training and a home walking program concurrent with CCRT. The program followed American College of Sports Medicine (ACSM) prescription guidelines for cancer patients and included strengthening, cardiovascular fitness, and physical activity components. Patients attended up to three sessions per week, lasting up to one hour as an eventual goal, including warm-up, cool down and rest periods. The warm-up included rhythmic large muscle movements such as marching and punching, while the cool down included leg, shoulder and arm flexibility activities coupled with deep breathing. Exercise intensity and duration was sometimes modified as the effect of CCRT intensified by the end of the 7<sup>th</sup> week, and later slowly increased as the effect waned. Participants were to perform the exercise program described below at a moderate intensity, as defined by 11-13 on a 20 point Rate of Perceived Exertion (RPE) scale.

Functional resistance training: The functional resistance training protocol was designed to minimize the loss of muscle mass associated with head and neck cancer and maintain and enhance physical activity levels during CCRT. Upper body musculature were targeted through whole body exercises to optimize the training effect while reducing exercise fatigue and augmenting lower extremity function. Emphasis was placed on the development of a sustainable exercise habit, including safe independent performance of the functional resistance training and exercises to include exercise progression and integration into daily activities. Exercises included: chest press in squat, wall push up, military press, side arm raises, biceps curl, shoulder shrugs, and calf raises. Weights included dumbbells and inserts into an ankle strap. Exercise duration and intensity were customized to the individual. The goal was to perform three 8-12 repetition sets of each functional resistance training exercise by the conclusion of the 7 week training period, to be customized in terms of repetitions and weights based on CCRT side effects. Limited rest periods (e.g. 2 minutes) were provided between sets to enhance the training effect.

Walking: For the cardiovascular and physical activity component, participants were given a pedometer, and the goal was to maintain step count based on the mean step count of the previous training week. Multiple short duration continuous walking periods were recommended, such as walking for 5 minutes 6 times throughout the day to achieve a total walking time of 30 minutes. Participants were also given information on optimal walking form, injury prevention, program progression, and ways to incorporate walking into daily life.

Home program: After the 7 week on-site training, MPACT participants were asked to integrate safe exercise activities into their own lifestyle through home activities. Participants were asked to perform their individualized functional resistance and walking program solely off-site for the last 7 weeks of the study (weeks 8-14). Each participant's functional resistance in addition to walking and physical activity program was customized based on: 1) personal determinants (self-efficacy, benefits, and barriers); 2) physical activity preferences; 3) available community resources; and 4) health and environmental factors. The goal was for participants to maintain their physical activity for a minimum of 5 days a week and a

minimum of 30 minutes per day, performed in bouts of 10 minutes or more, at a moderate intensity (RPE 11-13). The MPACT trainer made weekly telephone calls to facilitate home program adherence through week 14. The trainer addressed participant concerns and barriers (such as weight loss, changes in medications, and symptoms such as fatigue) and then used participant strengths to identify tailored solutions to help each participant reach and/or maintain the exercise and physical activity goals. At week 11, when the participant returned for follow-up to the radiation oncology clinic, the trainer met with the participant to go over their individualized program and review exercise technique.

#### Statistical Analysis:

*Baseline:* Participant characteristics were compared at baseline between MPACT and controls, using a two-tailed student's T-test for continuous variables (including functional mobility and SF-36 measures), Fisher's exact test for non-ordered categorical variables and Cochran-Armitage trend test for ordinal variables (e.g. head and neck cancer specific QoL individual questions or barriers to exercise).

*Baseline versus 7 and 14 weeks:* Changes in measures between baseline and week 7 or 14 were calculated for each patient and compared between MPACT and Control treatment groups. Per the protocol, a one-sided student's t-test was used to compare treatment groups with respect to mean change from baseline to 7 or 14 weeks for continuous outcomes. Mean change from baseline in Likert scale variables (such as the head and neck cancer QoL and Barriers to Exercise) was compared between treatment groups using Cochran-Armitage trend tests. All available data at each time point was used rather than selecting only patients who completed all time points. Statistical significance was set at  $p < 0.05$ . All statistical analyses were performed using R 3.0.1 statistical software (<http://www.r-project.org/>).

## **Results**

### Participant enrollment and attrition

Of the 27 consented participants, seven did not complete the program because they either withdrew, failed to meet screening criteria, or were deemed non-compliant prior to baseline testing and group allocation

**(Figure 1).** Ultimately 20 were allocated, 11 to MPACT and 9 patients to Control. Seventeen (10 MPACT and 7 control) completed 14 weeks on study. One MPACT participant discontinued all exercise sessions in the first week due to difficulty with multiple appointments, but continued to be assessed and so was included in the final analysis. Of the two control withdrawals, one refused the control group assignment and the second suffered a myocardial infarction. Excluding the MPACT participant who discontinued exercise in the first week, MPACT participants completed an average of 15.2 sessions out of a maximum 21 offered (72% attendance rate). The most common reason for not attending a session was cancer-related or treatment-related toxicity.

#### Participant baseline characteristics

**Table 1** shows the baseline characteristics for the 7 Control and 11 MPACT participants who completed the 14 week testing. Eleven of these 18 were Veterans. Mean age was 57 years for both groups and all patients were male except for a single University of Michigan female MPACT patient. The majority of patients had oropharyngeal primary tumors including the base of the tongue and tonsil. There were no significant differences between the two groups in chemotherapy, tumor stage, baseline PEG use, BMI, lean body mass, alcohol use (AUDIT score), smoking (Fagerstrom score), or Karnofsky score. Baseline muscle strength and functional mobility were similar between groups except for significantly higher knee extension strength in controls versus MPACT ( $p=0.04$ ). There were no significant differences at baseline in the SF-36 scores or subscores, MOS sleep, and physical activity based on the PASE questionnaire.

#### Baseline to 7 and 14 week changes in assessment outcomes (Table 2)

##### *Muscle strength*

Knee extension tended to be maintained for all 14 weeks in MPACT versus a decline in controls mostly by the 7<sup>th</sup> week, resulting in a significant mean 14 week decrease of 4 Newton-meters (N-m) for MPACT and 46 N-m for controls ( $p<0.05$ ) (**Figure 2**). There was no group difference in baseline to 7 or 14 week change in elbow flexion or grip strength.

### *Functional mobility*

The six minute walk test showed a trend toward less decline in MPACT than controls at 7 weeks (decrease of 71 feet in MPACT versus 166 feet in controls). MPACT tended to improve at 14 weeks versus baseline (by 60 feet) while controls decreased by 19 feet, although these differences were not statistically significant (**Figure 3**). Comfortable gait speed in MPACT and controls followed a trend at 7 and 14 weeks similar to six minute walk but timed up and go did not .

### *Quality of life and sleep*

Quality of life measured by SF-36 tended to show less decline and even improvement in MPACT versus controls when evaluating changes from baseline to 7 and 14 weeks. In MPACT versus controls and compared to baseline, overall SF-36 scores tended to decline less at 7 weeks (-19 vs. -24) and improved at 14 weeks (+4 versus -6, **Figure 4A**). The SF-36 physical summary measure declined similarly in both groups at 7 weeks but MPACT returned to baseline at 14 weeks compared to a continued deficit in controls (-3). The SF-36 mental summary score declined less in MPACT than controls by 7 weeks (-12 vs. -26) and improved in MPACT vs. continued decline in controls (+9 vs. -9). Of the other subscales evaluated that showed group differences, the SF-36 vitality subscale measuring energy and fatigue showed similar trends at 7 weeks (-19 for MPACT, -33 for controls,  $p<0.05$ ) and 14 weeks (+7 vs. -9) (**Figure 4B**). In addition, the SF-36 mental health subscale showed significant improvement in MPACT versus decline in controls at 7 weeks (+3 vs. -16,  $p<0.05$ ) and 14 weeks (+15 vs. -1,  $p<0.05$ ) (**Figure 4C**). The MOS Sleep Index tended to show continuous improvement in sleep disturbance in the MPACT group versus controls at weeks 7 (-5 vs. +8) and 14 (-14 vs. -1)

### *Head and neck specific quality of life*

Notable changes in head and neck specific quality of life survey items were in the same direction. When we examined the 21 items individually, one statistically significant finding was in emotional problems: MPACT participants reported fewer problems than controls when comparing 7 weeks to baseline ( $p<0.05$ ). No differences between the MPACT and the control groups were found in the change in overall

domain scores. Baseline domain scores were higher than previously described, largely driven by mean baseline scores for the VA patients (emotion: 55, communication: 42, eating: 38, pain: 52) that were significantly higher for every domain than for the University of Michigan patients (emotion: 24, communication: 14, eating: 13, pain: 26), consistent with prior results.<sup>(45-47)</sup>

#### *BMI and Lean body mass*

BMI declined by an average of 3 points by week 7 and 4-5 points by week 14 in both MPACT and control groups. Lean body mass tended to improve slightly by 7 weeks in MPACT (0.2%) and controls (1%) and more substantially by week 14 (5% and 4% respectively).

#### *Self-Reported and Objectively Assessed Physical Activity*

Using the PASE, the decline in self-reported physical activity was more attenuated at 7 weeks and tended to show greater improvement at 14 weeks compared to baseline in MPACT versus controls (7 weeks -65 vs. -96; 14 weeks +42 vs. -10 points, respectively). Objective physical activity monitoring via Actigraph assessment was available on a sub sample (4 MPACT and 3 Control) of participants. MPACT versus controls decreased less in the proportion of time spent in lifestyle activity by week 7 (3% versus 7% reduction, respectively), with MPACT returning back to baseline levels by week 14. Proportion of time spent in sedentary behavior increased less in MPACT versus controls by week 7 (4% versus 8% increase, respectively), and actually decreased overall by 2% in MPACT by week 14 (**Figure 5**). Postural transitions of sit to stand increased by 10 in MPACT by week 7, with some retention of this increase through week 14, compared to essentially no change in sit to stand transitions in controls.

#### *Barriers to Exercise*

Of the 34 barriers assessed, most showed no differences in change between groups, with two notable exceptions. Lack of interest in exercise as a barrier tended to be unchanged at 7 weeks in MPACT but was significantly more of a barrier in the Controls (0 vs. +1.6,  $p < 0.05$ ). Exercise being classified as boring was also more of a barrier at 7 weeks in the controls than in the MPACT group (+0.8 vs. -0.6,  $p < 0.05$ ).

#### *Diet*

Complete diet journals were available on a subsample (5 MPACT, and 3 control). Fruit and vegetable intakes at study start were about 2-3 servings/day, well below the USDA recommendation of 7-11/day, and dropped greatly as use of meal replacements increased. The decrease in fruit and vegetable consumption was less pronounced in MPACT and tended to be better maintained versus controls as seen in **Table 3**. There also was a trend for MPACT to return to solid foods more quickly than controls at week 7 (**Figure 6**).

#### *CCRT toxicity*

Reports of CCRT toxicity over the 14 week period did not differ between groups.

### **Discussion**

In this pilot controlled trial in head and neck cancer patients, we demonstrated the feasibility of a functional resistance and walking exercise intervention (MPACT, Maintaining Physical Activity during Cancer Treatment) provided during 7 weeks of concurrent chemotherapy with radiation (CCRT) and during 7 weeks of follow-up. Once enrolled, MPACT participants, despite the concurrent CCRT, completed 72% of the on-site exercise sessions. Ten of eleven (91%) of the MPACT participants completed the full 14-week program, with the 11th participant discontinuing training at week one.

As hypothesized, compared to controls and in evaluating changes from baseline to 7 and 14 weeks, MPACT participants tended to exhibit less CCRT-induced decline and even some improvement. These trends were found in nearly all measured domains, namely in muscle strength, functional mobility, quality of life, sleep disturbance, head and neck specific quality of life, self-reported and objectively assessed physical activity, barriers to exercise, and diet. Despite the small sample size, statistically significant changes in MPACT versus controls were noted in knee strength, mental health and head and neck QoL, and barriers to exercise.

Trends in changes favoring MPACT over controls in muscle strength and functional mobility occurred especially in knee extension strength and six minute walk distance. Despite the inclusion of whole body functional exercises, the MPACT focus on upright exercise likely favored lower extremity strength while the home program focus on increased walk time favored longer walk measures, such as the six-minute walk (versus shorter walk measures such as gait speed). For the six-minute walk, clinically meaningful changes in older adults have been proposed at two levels, small (20 m, 66 feet) and substantial (50 m, 164 feet)<sup>(48)</sup>. Thus, in the present study, MPACT participants exhibited a small meaningful decline at 7 weeks (-74 feet) and a small meaningful improvement at 14 weeks (+67 feet); controls exhibited substantial decline at 7 weeks (-166 feet) and minimal change (-3 feet) at 14 weeks.

Other studies during head and neck cancer treatment find analogous but sometimes conflicting training-induced changes in strength and functional mobility. Samuel et al<sup>(49)</sup> utilized a combined six week resistance training and walking program during CCRT and found similar results, with improvement in the six minute walk at six weeks of a median of 43 m versus a decline in the control group of a median of 96 m. In a small 12-week pilot of resistance-band training with a design analogous to the present study (six weeks on-site during CCRT and six weeks home-based following CCRT), the main tendency for resistance training (n=5) versus controls (n=8) was to reduce average time to rise from a chair but there was a decline in back/leg extensor strength.<sup>(50)</sup>

Studies conducted post-treatment for cancer utilized various interventions to improve muscle strength and functional mobility. Physiotherapy-guided training in a single group 8 week trial improved six minute walk distance<sup>(51)</sup> compared to self-selected physical activity controls, while 12 weeks of resistance training improved lean body mass and strength but not functional mobility.<sup>(52)</sup> No differences in BMI or lean body mass were seen in the present study between the control and intervention groups, possibly because the resistance training load was more functional and not at a high load (such as 80% of one



repetition maxima). In summary, exercise programs providing both resistance and walking training might improve muscle strength and functional mobility in head and neck cancer patients both during and after CCRT, with the suggestion that there is likely to be a degree of training specificity necessary (i.e. walking training to improve walking). Further controlled studies are needed with more prolonged follow-up<sup>(50)</sup> to evaluate how well these changes are maintained.

Tendencies for less decline and even improvement favoring MPACT over controls were noted in QoL measures, both general (particularly SF-36 physical summary, mental summary and vitality/fatigue scales) and head and neck cancer specific (particularly emotional problems). Statistically significant changes favoring MPACT were found in the SF-36 mental health scale, waking at night, and lack of interest in exercise. Using the proposed Reliable Change Index (RCI, the change between pre- and post-treatment scores that would be statistically and clinically reliable<sup>(53)</sup>), these differences in SF-36 change from baseline between groups are reliable at 14 weeks for the physical summary score (RCI=7), and at both 7 and 14 weeks for the mental summary score (RCI=10), the vitality subscore (RCI=10), and the mental health subscore (RCI=11). Other studies also have found QoL-related improvement with exercise programs in head and neck cancer participants, and there was often a greater effect in the mental health component. In Samuel et al<sup>(49)</sup>, intervention group median scores were stable (SF-36 physical component) or slightly improved (SF-36 mental component) while controls decreased in both, most strikingly on the mental component. Using the Functional Assessment of Cancer scales (FACT), Rogers et al<sup>(54)</sup> found tendencies favoring intervention over control for FACT-G (general), physical well-being, emotional well-being, and functional well-being, as well as a blunting of increases in the fatigue subscale, with no changes for head and neck-specific scores (FACT-H&N). This blunting of the fatigue subscale and, in the present study, the SF-36 vitality/fatigue scale, is consistent with literature showing that exercise mitigates cancer related fatigue.<sup>(44)</sup> Note that improvement in QoL may have been facilitated by the telephone trainer support contact; multidisciplinary rehabilitation programs which contain a psychosocial as well as

a physical component have been shown to improve SF-36 scores in cancer survivors in a large meta-analysis.<sup>(55)</sup>

Sleep disorders are another significant contributor to fatigue and decreased QoL in cancer patients<sup>(56)</sup>, and sleep quality is poorer in head and neck cancer patients compared to a healthy population<sup>(57)</sup>. In the present study, compared to controls, the MPACT group showed continuous improvement in this MOS Sleep-6. Factors in multiple domains likely influence sleep quality. Predictors of poor sleep quality among head and neck cancer patients, both at baseline and at one year follow-up include pain, xerostomia, depression, the presence of a tracheostomy tube, comorbidities and younger age<sup>(57)</sup>, none of which appeared to differ between the present study groups. Obstructive sleep apnea has also been recently proposed as a contributor to sleep disorders and fatigue in head and neck cancer patients.<sup>(58)</sup> Previous work suggests that decreased sleep is an independent predictor of increased inflammatory marker levels, specifically IL-6<sup>(59)</sup>. Elevated inflammatory markers are associated with cancer cachexia, muscle wasting, and radiation treatment<sup>51-52</sup>; on the other hand, exercise training may decrease inflammation as well as improve sleep in healthy older adults<sup>(60)</sup>. The impact of exercise training on sleep and inflammatory markers in head and neck cancer patients (and cancer patients in general) undergoing definitive treatment has not been carefully studied and may be an important new area of research.

Compared to controls, the decline in self-reported physical activity tended to be more attenuated in MPACT at 7 weeks and improved more by week 14. As noted in a previous review, physical activity (and exercise) is compromised in head and neck cancer patients.<sup>(8)</sup> Enjoyment of physical activity, task efficacy (confidence), and any alcohol use are positively correlated with physical activity while symptom index, comorbidity score, and perceived barriers are negatively correlated with physical activity<sup>(40)</sup>. There was little difference in reported barriers to exercise, although the MPACT group reported no change in lack of interest while controls increased in lack of interest. One possible contributor to the continued

interest and lack of difference in barriers may have been the support of the trainers, both on-site and in telephone follow-up. Providing feedback and support, and promoting knowledge and skills have been identified as key contributors to adherence in breast cancer strength training participants<sup>(61)</sup>. Taken along with the improvement in SF-36 mental health measures, future studies utilizing MPACT will need to explore the importance of cognitive-behavioral support and outcomes.

In order to determine feasibility for future studies, both actigraphy and diet were analyzed in small subsets, and appear to be feasible and follow the trends noted above. Actigraphy provided important objective trends favoring MPACT in maintaining lifestyle physical activity and avoiding more sedentary activity, and in showing an increase in posture changes from sitting to standing. These outcomes help to verify the attainment of physical activity goals based on ACSM guidelines and provide a more objective outcome for use in future intervention studies. In terms of diet, the MPACT group may have maintained their nutrition better and returned to eating solid foods faster than controls. This could reflect better physical function and recovery from treatment, but this observation, as well as the influence of diet on the other outcomes, have to be confirmed in larger studies.

One important study limitation is the small sample size, which limited the statistical power, but the assessment and intervention paradigm are feasible. An additional limitation of the study is that HPV status was not available for every patient. While we doubt that this would have changed the results of our study, it is possible that given the better prognosis of HPV positive patients they are even more likely to benefit from a physical activity program. The lack of a detailed record of adherence to the home program is an additional limitation. Future studies supplementing self-reported physical activity with objective measures such as actigraphy can help verify the extent of actual physical activity performed, both as a check for adherence and as an objective outcome measure. Strengths include the use of a control group, measures validated for use in cancer patients, an intervention that began with the start of cancer treatment

and continued in early post-treatment follow-up, an intervention oriented to functional strength, walking, and physical activity, and use of both an on-site and home-based intervention.

In summary, the MPACT functional resistance and walking exercise intervention for head and neck cancer patients, both during CCRT and afterwards, appears feasible. The findings of attenuation in decline during CCRT as well as improvements up through 14 weeks in the MPACT versus control groups suggest efficacy. Improvements tended to occur not just in physical, but also in mental/behavioral outcomes, suggesting a broader effect of the program. Data from this study can be used to guide a more extensive intervention with longer term follow-up to demonstrate long term maintenance and enhancement of post-CCRT recovery. The results of this study can guide care for cancer patients treated with CCRT and help address the long term physical and psychosocial rehabilitation needs of cancer survivors.

Acknowledgements: The authors would like to thank members of the research team who assisted with numerous aspects of planning and execution of the study: Deb Arnoldi, Michelle Baumgart, Brad Grincewicz, Jo Jennens, Gabriela Mueller, Martina Nabozny, Ayowale Oladeji, Eric Pear, Debbie Strasburg, Steven Kronenberg and Erica Twardzik. The authors would also like to acknowledge the support provided by the University of Michigan Cancer Center through the G. Clare Bishop, M.D. Memorial Fund, the Jerome & Mary Miller Cancer Fund and the Endowment for Discovery Fund, as well as the National Institute on Aging (P30 AG024824 and AG109675), the Office of Research and Development, Medical Service and Rehabilitation Research, the Development Service of the Department of Veterans Affairs, and the Dorothy and Herman Miller Fund for Mobility Research in Older Adults. We also thank all the patients who volunteered for this study.

Accepted Article

## References

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. *J Clin Oncol* 2006;24(14):2137-50.
2. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. *N Engl J Med* 2010;363(1):24-35.
3. Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. *J Clin Oncol* 2009;27(12):1992-8.
4. Duffy SA, Ronis DL, McLean S, et al. Pretreatment health behaviors predict survival among patients with head and neck squamous cell carcinoma. *J Clin Oncol* 2009;27(12):1969-75.
5. Duffy SA, Ronis DL, Valenstein M, et al. Depressive symptoms, smoking, drinking, and quality of life among head and neck cancer patients. *Psychosomatics* 2007;48(2):142-8.
6. Fingeret MC, Yuan Y, Urbauer D, Weston J, Nipomnick S, Weber R. The nature and extent of body image concerns among surgically treated patients with head and neck cancer. *Psychooncology* 2011.
7. Rhoten BA, Murphy B, Ridner SH. Body image in patients with head and neck cancer: a review of the literature. *Oral Oncol* 2013;49(8):753-60.
8. Hunter KU, Jolly S. Clinical review of physical activity and functional considerations in head and neck cancer patients. *Support Care Cancer* 2013;21(5):1475-9.
9. Chasen MR, Bhargava R. A descriptive review of the factors contributing to nutritional compromise in patients with head and neck cancer. *Support Care Cancer* 2009;17(11):1345-51.
10. Jager-Wittenaar H, Dijkstra PU, Vissink A, et al. Changes in nutritional status and dietary intake during and after head and neck cancer treatment. *Head Neck* 2011;33(6):863-70.
11. Jackson W, Alexander N, Schipper M, Fig L, Feng F, Jolly S. Characterization of changes in total body composition for patients with head and neck cancer undergoing chemoradiotherapy using dual-energy x-ray absorptiometry. *Head Neck* 2013.
12. Lenk K, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. *J Cachexia Sarcopenia Muscle* 2010;1(1):9-21.
13. Mick R, Vokes EE, Weichselbaum RR, Panje WR. Prognostic factors in advanced head and neck cancer patients undergoing multimodality therapy. *Otolaryngol Head Neck Surg* 1991;105(1):62-73.
14. O'Neill M, Heron DE, Flickinger JC, Smith R, Ferris RL, Gibson M. Posttreatment quality-of-life assessment in patients with head and neck cancer treated with intensity-modulated radiation therapy. *Am J Clin Oncol* 2011;34(5):478-82.
15. Pichard C, Kyle UG, Morabia A, Perrier A, Vermeulen B, Unger P. Nutritional assessment: lean body mass depletion at hospital admission is associated with an increased length of stay. *Am J Clin Nutr* 2004;79(4):613-8.
16. Rogers LQ, Courneya KS, Robbins KT, et al. Physical activity and quality of life in head and neck cancer survivors. *Support Care Cancer* 2006;14(10):1012-9.
17. Silver HJ, Dietrich MS, Murphy BA. Changes in body mass, energy balance, physical function, and inflammatory state in patients with locally advanced head and neck cancer treated with concurrent chemoradiation after low-dose induction chemotherapy. *Head Neck* 2007;29(10):893-900.
18. Taylor JC, Terrell JE, Ronis DL, et al. Disability in patients with head and neck cancer. *Arch Otolaryngol Head Neck Surg* 2004;130(6):764-9.
19. Schmitz KH, Courneya KS, Matthews C, et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. *Med Sci Sports Exerc* 2010;42(7):1409-26.

20. McNeely ML, Campbell KL, Rowe BH, Klassen TP, Mackey JR, Courneya KS. Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis. *CMAJ* 2006;175(1):34-41.
21. Mishra SI, Scherer RW, Snyder C, Geigle PM, Berlanstein DR, Topaloglu O. Exercise interventions on health-related quality of life for people with cancer during active treatment. *Clin Otolaryngol* 2012;37(5):390-2.
22. Monga U, Garber SL, Thornby J, et al. Exercise prevents fatigue and improves quality of life in prostate cancer patients undergoing radiotherapy. *Arch Phys Med Rehabil* 2007;88(11):1416-22.
23. Schneider CM, Hsieh CC, Sprod LK, Carter SD, Hayward R. Effects of supervised exercise training on cardiopulmonary function and fatigue in breast cancer survivors during and after treatment. *Cancer* 2007;110(4):918-25.
24. Segal RJ, Reid RD, Courneya KS, et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. *J Clin Oncol* 2003;21(9):1653-9.
25. Courneya KS, McKenzie DC, Mackey JR, et al. Effects of exercise dose and type during breast cancer chemotherapy: multicenter randomized trial. *J Natl Cancer Inst* 2013;105(23):1821-32.
26. Quist M, Langer SW, Rorth M, Christensen KB, Adamsen L. "EXHALE": exercise as a strategy for rehabilitation in advanced stage lung cancer patients: a randomized clinical trial comparing the effects of 12 weeks supervised exercise intervention versus usual care for advanced stage lung cancer patients. *BMC Cancer* 2013;13:477.
27. Jarden M, Moller T, Kjeldsen L, et al. Patient Activation through Counseling and Exercise--Acute Leukemia (PACE-AL)--a randomized controlled trial. *BMC Cancer* 2013;13:446.
28. Henke CC, Cabri J, Fricke L, et al. Strength and endurance training in the treatment of lung cancer patients in stages IIIA/IIIB/IV. *Support Care Cancer* 2014;22(1):95-101.
29. Jolly S, Peterson LA, Rozek LS, et al. Longitudinal changes in physical activity of head and neck squamous cell carcinoma patients. In: *ASCO Annual Meeting; 2013; 2013*.
30. Taves DR. Minimization: a new method of assigning patients to treatment and control groups. *Clin Pharmacol Ther* 1974;15(5):443-53.
31. Beauchet O, Fantino B, Allali G, Muir SW, Montero-Odasso M, Annweiler C. Timed Up and Go test and risk of falls in older adults: a systematic review. *J Nutr Health Aging* 2011;15(10):933-8.
32. Ware JE, Jr., Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. *J Clin Epidemiol* 1998;51(11):903-12.
33. Hays RD, Martin SA, Sesti AM, Spritzer KL. Psychometric properties of the Medical Outcomes Study Sleep measure. *Sleep Med* 2005;6(1):41-4.
34. Washburn RA, Smith KW, Jette AM, Janney CA. The Physical Activity Scale for the Elderly (PASE): development and evaluation. *J Clin Epidemiol* 1993;46(2):153-62.
35. Troiano RP, Berrigan D, Dodd KW, Masse LC, Tilert T, McDowell M. Physical activity in the United States measured by accelerometer. *Med Sci Sports Exerc* 2008;40(1):181-8.
36. Masse LC, Fuemmeler BF, Anderson CB, et al. Accelerometer data reduction: a comparison of four reduction algorithms on select outcome variables. *Med Sci Sports Exerc* 2005;37(11 Suppl):S544-54.
37. Freedson PS, Melanson E, Sirard J. Calibration of the Computer Science and Applications, Inc. accelerometer. *Med Sci Sports Exerc* 1998;30(5):777-81.
38. Matthew CE. Calibration of accelerometer output for adults. *Med Sci Sports Exerc* 2005;37(11 Suppl):S512-22.
39. Terrell JE, Nanavati KA, Esclamado RM, Bishop JK, Bradford CR, Wolf GT. Head and neck cancer-specific quality of life: instrument validation. *Arch Otolaryngol Head Neck Surg* 1997;123(10):1125-32.
40. Rogers LQ, Courneya KS, Robbins KT, et al. Physical activity correlates and barriers in head and neck cancer patients. *Support Care Cancer* 2008;16(1):19-27.

41. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. *Br J Addict* 1991;86(9):1119-27.
42. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. *Addiction* 1993;88(6):791-804.
43. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. *Semin Radiat Oncol* 2003;13(3):176-81.
44. McNeely ML, Courneya KS. Exercise programs for cancer-related fatigue: evidence and clinical guidelines. *J Natl Compr Canc Netw* 2010;8(8):945-53.
45. Feng FY, Kim HM, Lyden TH, et al. Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results. *J Clin Oncol* 2010;28(16):2732-8.
46. Vainshtein JM, Griffith KA, Feng FY, Vineberg KA, Chepeha DB, Eisbruch A. Patient-reported voice and speech outcomes after whole-neck intensity modulated radiation therapy and chemotherapy for oropharyngeal cancer: prospective longitudinal study. *Int J Radiat Oncol Biol Phys* 2014;89(5):973-80.
47. Lin A, Kim HM, Terrell JE, Dawson LA, Ship JA, Eisbruch A. Quality of life after parotid-sparing IMRT for head-and-neck cancer: a prospective longitudinal study. *Int J Radiat Oncol Biol Phys* 2003;57(1):61-70.
48. Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful change and responsiveness in common physical performance measures in older adults. *J Am Geriatr Soc* 2006;54(5):743-9.
49. Samuel SR, Maiya GA, Babu AS, Vidyasagar MS. Effect of exercise training on functional capacity & quality of life in head & neck cancer patients receiving chemoradiotherapy. *Indian J Med Res* 2013;137(3):515-20.
50. Capozzi LC, Lau H, Reimer RA, McNeely M, Giese-Davis J, Culos-Reed SN. Exercise and nutrition for head and neck cancer patients: a patient oriented, clinic-supported randomized controlled trial. *BMC Cancer* 2012;12:446.
51. Eades M, Murphy J, Carney S, et al. Effect of an interdisciplinary rehabilitation program on quality of life in patients with head and neck cancer: review of clinical experience. *Head Neck* 2013;35(3):343-9.
52. Lonbro S, Dalgas U, Primdahl H, et al. Progressive resistance training rebuilds lean body mass in head and neck cancer patients after radiotherapy--results from the randomized DAHANCA 25B trial. *Radiother Oncol* 2013;108(2):314-9.
53. Ferguson RJ, Robinson AB, Splaine M. Use of the reliable change index to evaluate clinical significance in SF-36 outcomes. *Qual Life Res* 2002;11(6):509-16.
54. Rogers LQ, Anton PM, Fogleman A, et al. Pilot, randomized trial of resistance exercise during radiation therapy for head and neck cancer. *Head Neck* 2013;35(8):1178-88.
55. Scott DA, Mills M, Black A, et al. Multidimensional rehabilitation programmes for adult cancer survivors. *Cochrane Database Syst Rev* 2013;3:CD007730.
56. Roscoe JA, Kaufman ME, Matteson-Rusby SE, et al. Cancer-related fatigue and sleep disorders. *Oncologist* 2007;12 Suppl 1:35-42.
57. Shuman AG, Duffy SA, Ronis DL, et al. Predictors of poor sleep quality among head and neck cancer patients. *Laryngoscope* 2010;120(6):1166-72.
58. Zhou J, Jolly S. Obstructive Sleep Apnea and Fatigue in Head and Neck Cancer Patients. *Am J Clin Oncol* 2014.
59. Duffy SA, Teknos T, Taylor JM, et al. Health behaviors predict higher interleukin-6 levels among patients newly diagnosed with head and neck squamous cell carcinoma. *Cancer Epidemiol Biomarkers Prev* 2013;22(3):374-81.



60. Santos RV, Viana VA, Boscolo RA, et al. Moderate exercise training modulates cytokine profile and sleep in elderly people. *Cytokine* 2012;60(3):731-5.
61. McGuire R, Waltman N, Zimmerman L. Intervention components promoting adherence to strength training exercise in breast cancer survivors with bone loss. *West J Nurs Res* 2011;33(5):671-89.

Accepted Article

*Figure Legends*

**Figure 1.** Study flow diagram.

**Figure 2.** Group mean (SE) change in knee extension strength (in newton-meters) at 7 and 14 weeks. (MPACT n=11, control n=7). \*p<0.05.

**Figure 3.** Group mean (SE) change in six minute walk distance (in feet) at 7 and 14 weeks. (MPACT n=11, control n=7).

**Figure 4.** Group mean (SE) change in SF-36 scores at 7 and 14 weeks: **(A)** Total SF-36 score; **(B)** Vitality subscore; **(C)** Mental health subscore. (MPACT n=11, control n=7). \*p<0.05.

**Figure 5.** Group mean (SE) change in proportion of time spent in sedentary behavior, as measured by actigraphy, at 7 and 14 weeks (MPACT n=4, control n=3).

**Figure 6.** Group mean (SE) solid food servings per day at 1, 4, 6, and 7 weeks (MPACT n=5, control n=3).

Table 1: Baseline Participant Characteristics

	MPACT (n=11)	Controls (n=7)	p-value
Age in years	57 (7)	57 (7)	0.9
Institution			
VA	7	4	1.0
UM	4	3	
Tumor Location			
Larynx	1	0	1.0
Nasopharynx	1	0	
Oropharynx	8	6	
Unknown Primary	1	1	
Stage			
Stage III	4	0	0.1
Stage IV	7	7	
Chemotherapy			
Platinum Only	9	5	1.0
Taxol + Platinum	2	2	
Body Mass Index	30 (5)	32 (3)	0.4
Percent Lean Body Mass	62 (9)	62 (5)	1.0
Karnofsky Performance Score			
< 90	1	3	0.2
≥ 90	8	3	
NA	2	1	
Six Minute Walk Distance (feet)	1400 (243)	1530 (233)	0.3
Elbow Flexion (n-m)	54 (16)	60 (22)	0.6
Knee Extension (n-m)	154 (44)	224 (67)	0.04*
Grip Strength (kg)	42 (8)	45 (9)	0.5
TUG (sec)	8 (3)	8 (1)	0.6
Gait Speed (m/s)	1.3 (0.2)	1.5 (0.2)	0.8
MOS Sleep Score	34 (19)	41 (20)	0.5
PASE	147 (90)	150 (116)	1.0
SF36			
Physical	67 (20)	56 (23)	0.3
Mental	61 (29)	60 (26)	0.9
Physical Function	82 (19)	69 (26)	0.3
Role-Physical	50 (39)	36 (45)	0.5
Role-Emotional	64 (46)	57 (54)	0.8
Vitality	58 (23)	54 (21)	0.7
Mental Health	62 (27)	67 (28)	0.7
Social Functioning	60 (33)	61 (38)	1.0
Pain	50 (31)	31 (8)	0.1
General Health	58 (18)	55 (17)	0.8
AUDIT (Alcohol)	4 (4)	3 (4)	1.0
Fagerstrom (Smoking)	2 (4)	3 (4)	0.9
Barriers to exercise			
Lack of interest	2.6 (1.3)	2.8 (1.8)	0.7

Exercise is boring	2.2 (1.3)	2.1 (1.7)	1.0
HNCa related QoL			
Domain: Emotion	47 (28)	38 (28)	0.5
Domain: Communication	23 (23)	44 (34)	0.2
Domain: Eating	23 (20)	38 (35)	0.3
Domain: Pain	37 (28)	49 (24)	0.3

Numbers represent number of patients (n) or mean value (standard deviation). All 18 patients (everyone who began and did not subsequently withdraw from the study) are included, regardless of whether or not they completed all sessions

\*p < 0.05

Accepted Article

Table 2. Mean (SE) Change in Assessment Outcome at Weeks 7 and 14

Measure	Mean (SE) change at 7 weeks		Mean (SE) change at 14 weeks	
	MPACT (n=11)	Control (n=7)	MPACT (n=11)	Control (n=7)
<i>Physical performance</i>				
Knee extension strength (n-m)	1 (11)	-36 (16)*	-4 (7)	-46 (14) <sup>#</sup>
6 Minute Walk distance (feet)	-71 (36)	-166 (93)	60 (40)	-19 (89)
Comfortable gait speed (m/s)	-0.08 (0.04)	-0.14 (0.09)	0.02 (0.04)	-0.05 (0.06)
Timed up and Go (s)	0.7 (0.8)	-0.07 (0.7)	-0.7 (0.6)	-0.2 (0.6)
<i>Quality of life and sleep</i>				
Overall SF-36	-19 (5)	-24 (5)	4 (4)	-6 (8)
SF-36 Physical summary	-24 (6)	-22 (8)	1 (4)	-3 (8)
SF-36 Mental summary	-12 (7)	-26 (6)	9 (4)	-9 (12)
SF-36 subscale: Vitality	-19 (7)	-33 (3)*	7 (5)	-9 (10)
SF-36 subscale: Mental Health	3 (4)	-16 (7)*	15 (4)	-1 (6) <sup>#</sup>
MOS Sleep Index	-5 (5)	8 (6)	-14 (5)	-1 (11)
<i>BMI and lean body mass</i>				
BMI	-2.9 (0.6)	-3 (0.5)	-3.9 (0.7)	-4.6 (0.6)
Lean body mass (percent)	0.2 (0.5)	1.0 (0.7)	4.7 (1.5)	4.0 (0.9)
<i>Self reported physical activity</i>				
PASE	-65 (24)	-96 (35)	42 (18)	-10 (31)
<i>Objective physical activity</i>				
	(n=4)	(n=3)	(n=4)	(n=3)
Proportion of lifestyle minutes	-0.03 (0.01)	-0.07 (0.03)	0.00 (0.01)	-0.03 (0.01)
Proportion of sedentary minutes	0.04 (0.02)	0.08 (0.02)	-0.02 (0.02)	0.06 (0.03)
Number of sit-to-stand transitions	11.5 (7.9)	-2.7 (5.2)	6.7 (8.9)	1.8 (2.1)


\* refers to  $p < 0.05$  when comparing MPACT vs. control from baseline to 7-weeks

<sup>#</sup> refers to  $p < 0.05$  when comparing MPACT vs. control from baseline to 14-weeks

Table 3. Mean (SE) Dietary Journal Assessments in MPACT (n=5) and Controls (n=3)

Measure	Week 1		Week 4		Week 6		Week 7	
	MPACT	Control	MPACT	Control	MPACT	Control	MPACT	Control
Fruit and vegetable servings	1.8 (0.6)	2.9 (0.6)	1.1 (0.4)	1.7 (0.5)	1.2 (0.6)	0.7 (0.5)	1.4 (0.8)	0.5 (0.3)
Solid Food servings	6.3 (1.0)	7.2 (1.3)	3.8 (1.5)	4.5 (0.4)	2.6 (1.2)	1.7 (0.9)	3.6 (1.7)	1.2 (0.7)
Meal replacements	1.1 (0.8)	0.4 (0.3)	3.3 (1.6)	1.4 (0.6)	3.4 (1.4)	3.5 (1.4)	2.5 (0.8)	3.3 (1.3)

Accepted Article



*\*Participant (n=1) discontinued MPACT training due to appointment burden but completed 7 and 14 week evaluations.*

Figure 1. Study flow diagram.  
279x361mm (300 x 300 DPI)






Figure 2. Group mean (SE) change in knee extension strength (in newton-meters) at 7 and 14 weeks. (MPACT n=11, control n=7). \*p<0.05.  
279x361mm (300 x 300 DPI)








Figure 3. Group mean (SE) change in six minute walk distance (in feet) at 7 and 14 weeks. (MPACT n=11, control n=7).  
279x361mm (300 x 300 DPI)






Figure 4. Group mean (SE) change in SF-36 scores at 7 and 14 weeks: (A) Total SF-36 score; (B) Vitality subscore; (C) Mental health subscore. (MPACT n=11, control n=7). \*p<0.05  
279x361mm (300 x 300 DPI)




Figure 5. Group mean (SE) change in proportion of time spent in sedentary behavior, as measured by actigraphy, at 7 and 14 weeks (MPACT n=4, control n=3).  
279x361mm (300 x 300 DPI)






Figure 6. Group mean (SE) solid food servings per day at 1, 4, 6, and 7 weeks (MPACT n=5, control n=3).  
279x361mm (300 x 300 DPI)

A